Published on
Monday, July 16, 2012
While reimbursement consultants say France's Haute
Autorite de Sante (HAS) is more predictable than Germany's Institute for
Quality and Efficiency in Health Care (IQWiG) and Germany's Federal
Joint Committee (G-BA), the data also show HAS in some cases has been more
stringent in its evaluation of the comparative benefit of newly approved drugs
than IQWiG and G-BA. On the other hand, Germany's narrower definition of
patient-relevant benefit makes it harder to get premium pricing in that country.
Of 18 drugs assessed by both countries, three had
French ASMR ratings showing a greater additional benefit in at least one
subpopulation compared to IQWiG/G-BA, while five drugs were deemed more
innovative by IQWiG/G-BA than by HAS. The agencies had similar assessments for
10 drugs. Six drugs with IQWiG/G-BA assessments have yet to be assessed in
France.